PRDX2 and breast carcinoma: More recently, the presence of full-length recombinant proteins—alpha 1-antitrypsin (A1AT), triose-phosphate isomerase 1 (TPI1), peptidyl-prolyl cis-trans isomerase A (PPIA), and peroxiredoxin 2 (PRDX2)—as microarrays evaluated potential antigens associated with early-stage breast cancer tumors [10].